Mitchell 1995.

Methods	Cross‐over, placebo controlled, double‐blind study. Duration: 4 week placebo, 16 weeks medication/placebo, 4 weeks placebo, 16 weeks medication/placebo, 4 weeks placebo
Participants	Country: England Single centre Diagnosis: MND diagnosed by two consultant neurologists Number of participants: 56 (66% male) Age: not stated Inclusion criteria: not stated Exclusion criteria: not stated
Interventions	1. Selegiline 10 mg daily 2. Placebo
Outcomes	Primary: not stated Other: hand held myometry, hand grip strength, Barthel Disability Index, Rankin Disability Scale, Bulbar Rating Scale, Quality of Life Scale. Whole blood and serum glutathione peroxidase, erythrocyte SOD, serum caeruloplasmin, leucocyte and plasma ascorbic acid, serum tocopherol
Notes	This is published as a letter with no details of clinical results. Additional details are given in Mitchell 1994, and in unpublished information provided by Professor Mitchell
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: not addressed
Allocation concealment (selection bias)	Unclear risk	Comment: not addressed
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"double blind" Comment: probably adequate
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: not addressed
Selective reporting (reporting bias)	Low risk	Comment: appears adequate
Other bias	Unclear risk	Comment: insufficient information